IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the...
LAWRENCEVILLE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will...
Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company’s large, randomized Phase II study, OVATION 2...
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism First-of-its-kind meeting spotlights IMNN-001...
Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD) Higher ctDNA clearance...
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer...
LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy...
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3...
IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment...
LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company...